Search

Displaying results 2821 - 2830 of 10000 in total
  1. Drug

    Benzethonium

    go.drugbank.com/drugs/DB11125
    Approved

    It is additionally found in cosmetics and toiletries such as mouthwashes and anti-itch ointments. … It is shown to be effective in mediating its antimicrobial action against bacteria, fungi, mold and viruses.

    Products: Ca-rezz - Norisc - Incontinent Wash, Ca-rezz Norisc Antibacterial Skin Care
  2. Drug

    Tizanidine

    go.drugbank.com/drugs/DB00697
    ApprovedInvestigational

    Tizanidine is a fast-acting drug used for the management of muscle spasm, which may result from the effects of multiple sclerosis, stroke, an acquired brain injury, or a spinal cord injury [T574]. … Initially approved by the FDA in 1996, tizanidine is an Alpha-2 adrenergic receptor agonist reducing spasticity by the presynaptic inhibition of excitatory neurotransmitters that cause firing of neurons

    Mixtures: ALERTADINA® A TABLETAS RECUBIERTASCategories: Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index
  3. Drug

    Atracurium besylate

    go.drugbank.com/drugs/DB00732
    Approved

    A non-depolarizing neuromuscular blocking agent with short duration of action. … Its lack of significant cardiovascular effects and its lack of dependence on good kidney function for elimination provide clinical advantage over alternate non-depolarizing neuromuscular blocking agents

  4. Drug

    Minocycline

    go.drugbank.com/drugs/DB01017
    ApprovedInvestigational

    Minocycline was first described in the literacture in 1966.[A190681] It is a second generation tetracycline antibiotic that is active against gram-negative and gram-positive bacteria. … [A190723] Minocycline was granted FDA approval on 30 June 1971.[L11695]

    Products: MINOCYCLIN 1A PHARMA 50MG, AA-Minocycline 50mg Capsule
  5. Drug

    Zopapogene imadenovec

    go.drugbank.com/drugs/DB24672
    ApprovedInvestigational

    [L54081] Zopapogene imadenovec is a non-replicating adenoviral vector–based immunotherapy that expresses a fusion antigen from selected regions of HPV-6/11 proteins to elicit an immune response in RRP. … Recurrent respiratory papillomatosis (RRP) is a rare, debilitating disease driven by chronic human papillomavirus (HPV) 6 or 11 infection and characterized by recurrent benign tumors in the respiratory

    Synonyms: under control of a human cytomegalovirus (CMV) promoter and terminated with a 3' untranslated region and a simian virus 40 (SV40) polyadenylation signal, DNA (recombinant replication-deficient Gorilla gorilla gorilla adenovirus strain GC4 vector PRGN-2012 human cytomegalovirus promoter plus human papillomavirus 6/11 E2, E4, E6, E7 protein 11 epitope-containing
  6. Drug

    Gestrinone

    go.drugbank.com/drugs/DB11619
    Approved

    Gestrinone was developed in the early 1970s and was tested clinically as a weekly oral contraceptive in Europe and North America. … Gestrinone, also known as ethylnorgestrienone, is a synthetic steroid of the 19-nortestosterone group that is marketed in Europe, Australia, and Latin America, though not the United States or Canada, and

  7. Drug

    Desmopressin

    go.drugbank.com/drugs/DB00035
    ApprovedInvestigational

    First synthesized in the 1960s, desmopressin has remained a gold-standard therapy for water balance disorders due to its safety and long duration of action compared to natural AVP [A31661, A275461]. … On January 15, 2026, the FDA approved a new low-dose sublingual film formulation specifically for the treatment of nocturia in patients at high risk for fluid overload, utilizing a specialized delivery

  8. Drug

    Methantheline

    go.drugbank.com/drugs/DB00940
    Approved

    Methantheline is a synthetic antispasmodic. Antispasmodics are used to relieve cramps or spasms of the stomach, intestines, and bladder. … intestine or stomach ulcers (peptic ulcer disease), intestine problems (irritable bowel syndrome), pancreatitis, gastritis, biliary dyskinesia, pylorosplasm, or urinary problems (reflex neurogenic bladder in

  9. Drug

    Rusfertide

    go.drugbank.com/drugs/DB17724
    ApprovedInvestigational

    Rusfertide is a hepcidin mimetic used to treat erythrocytosis in adults with polycythemia vera. … [L64098] The FDA approved rusfertide on August 28, 2026 for the treatment of erythrocytosis in adults with polycythemia vera, a blood cancer.

  10. Drug

    Tolvaptan

    go.drugbank.com/drugs/DB06212
    ApprovedInvestigational

    FDA approved on May 19, 2009.

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index